Postpartum Depression Market Trends Point to Steady Growth Ahead by 2034, DelveInsight Analysis Reveals | SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers

The Key Postpartum Depression Companies in the market include - SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others.

DelveInsight's "Postpartum Depression Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Postpartum Depression, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Postpartum Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Postpartum Depression Market Forecast [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Postpartum Depression Market Report

*
The Postpartum Depression market size was valued ~USD 260 million in 2023 among the 7MM countries and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In December 2025, Biogen Canada Inc. has announced that Health Canada has granted a Notice of Compliance (NOC) for ZURZUVAE Trademark (zuranolone) to treat moderate to severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral treatment for women with PPD. Clinical studies show this pioneering therapy can relieve depressive symptoms as early as day 3, with significant symptom reduction by day 15, and effects that are sustained through day 45 compared to placebo.

*
In July 2025, Biogen Inc. (Nasdaq: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing approval for ZURZUVAE Registered (zuranolone) to treat postpartum depression (PPD) in adults after childbirth. If the European Commission (EC) grants approval, ZURZUVAE would become the first therapy in the EU specifically indicated for depressive symptoms in women with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment, previously approved by the U.S. FDA in 2023.

*
In June 2025, Lipocine has begun dosing participants in its two-arm, blinded, randomized Phase III study evaluating LPCN 1154 (oral brexanolone) for postpartum depression (PPD). This advancement comes after the FDA provided feedback permitting the trial to be conducted in an outpatient setting, eliminating the requirement for continuous medical supervision. The company anticipates using the results from this trial to support a New Drug Application (NDA) submission planned for mid-2026.

*
In March 2025, Lipocine has initiated a randomized Phase III clinical trial for LPCN 1154, an oral formulation of brexanolone designed to treat postpartum depression (PPD). The trial follows a pharmacokinetic bridge study, which compared LPCN 1154's exposure to that of the reference drug. The company expects to dose the first participant in the second quarter of this year.

*
In May 2024, Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, announced today the completion of subject dosing in the pivotal pharmacokinetic (PK) study intended to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154, an oral formulation of brexanolone, is being developed as a treatment for postpartum depression (PPD).

*
Among the EU4 countries and the UK, the UK had the largest market size for Postpartum Depression, estimated at approximately USD 25 million in 2023.

*
By 2034, ZURZUVAE is anticipated to generate approximately USD 600 million in revenue from the postpartum depression therapeutics market across the 7MM.

*
Among the EU4 countries and the UK, the UK had the largest postpartum depression market size, approximately USD 25 million in 2023.

*
In 2023, Japan's postpartum depression market size was approximately USD 20 million, with a moderate growth expected by 2034.

*
In 2023, the total number of diagnosed postpartum depression cases across the seven major countries was approximately 1,310,000.

*
In 2023, the total number of diagnosed postpartum depression cases in the EU4 countries and the UK was approximately 460,000.

*
In 2023, the United States had the highest number of diagnosed postpartum depression cases among the seven major markets, totaling approximately 720,000, followed by the UK.

*
In 2023, Japan had approximately 126,000 diagnosed prevalent cases of postpartum depression.

*
ZURZUVAE (zuranolone) and ZULRESSO (brexanolone) are the only approved treatments for postpartum depression (PPD). ZULRESSO is given as a continuous intravenous (IV) infusion, while the recommended dosage for ZURZUVAE is 50 mg taken orally for 14 days. Leading companies working on new PPD therapies include Sage Therapeutics, Marinus Pharmaceuticals, Lipocine, and Brii Biosciences.

*
Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others

*
Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, and others

*
The Postpartum Depression epidemiology based on gender analyzed that PPD majorly affects females but a small proportion of males can also experience depression post-pregnancy

*
The Postpartum Depression market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Postpartum Depression pipeline products will significantly revolutionize the Postpartum Depression market dynamics.

Postpartum Depression Overview

Postpartum depression (PPD) is a complex emotional and psychological condition that affects women after childbirth. It typically occurs within the first few weeks to months following delivery and is characterized by feelings of extreme sadness, anxiety, and fatigue, which can significantly impact a mother's ability to care for herself and her baby.

Get a Free sample for the Postpartum Depression Market Report:

https://www.delveinsight.com/report-store/postpartum-depression-ppd-market [https://www.delveinsight.com/report-store/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Postpartum Depression Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Postpartum Depression Epidemiology Segmentation:

The Postpartum Depression market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Postpartum Depression

*
Prevalent Cases of Postpartum Depression by severity

*
Gender-specific Prevalence of Postpartum Depression

*
Diagnosed Cases of Episodic and Chronic Postpartum Depression

Download the report to understand which factors are driving Postpartum Depression epidemiology trends @ Postpartum Depression Epidemiology Forecast [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Postpartum Depression Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postpartum Depression market or expected to get launched during the study period. The analysis covers Postpartum Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Postpartum Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Postpartum Depression Therapies and Key Companies

*
Zuranolone(SAGE-217): SAGE Therapeutics

*
BRII-296: Brii Biosciences Limited

*
RE104: Reunion Neuroscience

*
GH001: GH Research

*
Brexanolone: Sage Therapeutics

*
aripiprazole: Bristol-Myers Squibb

Discover more about therapies set to grab major Postpartum Depression market share @ Postpartum Depression Treatment Market [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Postpartum Depression Market Drivers

*
ZULRESSO starts working within 2-3 days of the administration, drastically improving the response rates compared to conventional therapies

*
Therapies like BRII-296 and LPCN-1154 are in early stages of clinical development and their approval in future can help the PPD therapeutic market grow tremendously.

Postpartum Depression Market Barriers

*
Limited therapies are available for treating and diagnosing PPD, thus providing profitable opportunities for emerging therapies

*
Increasing research and development to establish the pathophysiology and recent advancement in the diagnosis gives alucrative opportunity for the PPD market

Scope of the Postpartum Depression Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Postpartum Depression Companies: SAGE Therapeutics, Brii Biosciences Limited, Reunion Neuroscience, GH Research, Bristol-Myers Squibb, and others

*
Key Postpartum Depression Therapies: Zuranolone(SAGE-217), BRII-296, RE104, GH001, Brexanolone, aripiprazole, and others

*
Postpartum Depression Therapeutic Assessment: Postpartum Depression current marketed and Postpartum Depression emerging therapies

*
Postpartum Depression Market Dynamics: Postpartum Depression market drivers and Postpartum Depression market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Postpartum Depression Unmet Needs, KOL's views, Analyst's views, Postpartum Depression Market Access and Reimbursement

To know more about Postpartum Depression companies working in the treatment market, visit @ Postpartum Depression Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/postpartum-depression-ppd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Postpartum Depression Market Report Introduction

2. Executive Summary for Postpartum Depression

3. SWOT analysis of Postpartum Depression

4. Postpartum Depression Patient Share (%) Overview at a Glance

5. Postpartum Depression Market Overview at a Glance

6. Postpartum Depression Disease Background and Overview

7. Postpartum Depression Epidemiology and Patient Population

8. Country-Specific Patient Population of Postpartum Depression

9. Postpartum Depression Current Treatment and Medical Practices

10. Postpartum Depression Unmet Needs

11. Postpartum Depression Emerging Therapies

12. Postpartum Depression Market Outlook

13. Country-Wise Postpartum Depression Market Analysis (2020-2034)

14. Postpartum Depression Market Access and Reimbursement of Therapies

15. Postpartum Depression Market Drivers

16. Postpartum Depression Market Barriers

17. Postpartum Depression Appendix

18. Postpartum Depression Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=postpartum-depression-market-trends-point-to-steady-growth-ahead-by-2034-delveinsight-analysis-reveals-sage-therapeutics-brii-biosciences-limited-reunion-neuroscience-gh-research-bristolmyers]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.